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ABSTRACT 
 
Currently, umbilical cord mesenchymal stem cells have the potential to be used as treatment options for any cartilage 
lesion. This research aimed to evaluate the effects of conditioned medium from umbilical cord mesenchymal stem 
cells (UC-MSC) on damaged cartilage through the expression of proteins TGF-β1, SOX-9, type II collagen and 
aggrecan, which are known to be related to chondrogenesis. UC-MSC were isolated from 19-days-pregnant Wistar 
mice and were cultured using the standard procedure to obtain 80% confluence. Subsequently, the culture was 
confirmed through a microscopic examination that was driven to be an embryoid body to obtain a pre-condition 
medium. This research utilized 3-month-old male Wistar mice and was categorized into 6 groups (3 control and 3 
treatment groups). Each animal had surgery performed to create a femur condyle cartilage defect. The treatment 
groups were administered a dose of stem cells at 1 mL/kg. Next, immunohistochemical (IHC) staining was per-
formed to examine the expression of TGF-β1, SOX-9, type II collagen and aggrecan in the 2nd, 3rd, and 4th month 
of evaluation. The results were analyzed statistically using ANOVA test. For each of the treatment groups, there was 
increased expression (p < 0.05) in all proteins TGF-β1, SOX-9, type II collagen and aggrecan when compared with 
control groups at the 2nd, 3rd, and 4th month of evaluation. Pre-conditioned medium from UC-MSC potentially 
increases the expression of TGF-β1, SOX-9, type II collagen and aggrecan in the damaged cartilage of Wistar mice. 
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INTRODUCTION 
Stem cell-derived conditioned medium (CM) has 
the potential to be produced as a treatment option for 
regenerative medicine. The use of secretome containing 
CM has several advantages when compared to the use 
of stem cells. Briefly, CM can be manufactured, freeze-
dried, packaged, and transported with greater ease [1]. 
Moreover, as it is devoid of cells there is a lower risk of 
host rejection. To date, there is limited data pertaining 
to the use of CM for cartilage repair. 
Mesenchymal stem cells (MSC) are a population of 
cells with infinite proliferation capability and the poten-
tial to differentiate into cells of the mesoderm lineage. 
Research studies have reported that MSC has the capa- 
bility to differentiate into osteoblasts, chondrocytes, car-
diomyocytes, myocytes, adipose cells and even neural 
cells. MSC can be isolated from multiple areas in adult 
tissue such as bone marrow, adipose tissue, umbilical 
cords, and peripheral blood [2, 3, 4]. Umbilical Cord 
Derived Mesenchymal Stem Cells (UC-MSCs) have pro-
liferation and differentiation capabilities. These stem 
cells have also been shown to have the ability to differ-
entiate into unipotent cells that have a chondrocyte pat-
tern [5]. 
Deterioration of cartilage leads to osteoarthritis, a 
disease through which articular chondrocytes become 
deformed, or fibrillated losing their cartilage forming 
function. There are several proteins that are associated 
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with chondrogenesis. TGF-β1 promotes chondrogenesis 
in cultures of early-undifferentiated MSC in vitro and 
stimulates chondrogenic differentiation in vivo [6]. Pre-
vious studies reported that expression and activity of 
TGF-β1 signaling could potentially have detrimental ef-
fects on mature condylar cartilages [12]. TGF-β1 has an 
ability to down regulate type II collagen and aggrecan in 
articular chondrocytes via the SOX-9 protein [7]. SOX-
9 is a transcription factor belonging to the Sry-type 
HMG-box (SOX) protein family, which is essential for 
chondrogenesis and has been termed a “master regula-
tor” of the chondrocyte phenotype. In addition, SOX-9 
has been shown to activate type II collagen and aggre-
can. Moreover, SOX-9 prevents chondrocyte hypertro-
phy and has a redifferentiation effect on osteoarthritic 
chondrocytes, which have been dedifferentiated. Type II 
Collagen, a major component of hyaline cartilage, has 
many advantages as a biomaterial for chondrogeneses, 
such as biodegradability and the capability to induce re-
pair processes in articular cartilage [8]. Aggrecan is one 
of the major components of cartilage and binds to hya-
luronan (HA) and links proteins to form huge aggre-
gates. These aggregates lead to a hydrated gel-like struc-
ture of cartilage and resistibility to compression and de-
formation in joints [9]. 
Currently, there has been vast research to study fac-
tors that promote cartilage repair. However, only a few 
describe the secretome of UC-MSC in chondrogenesis 
has been reported. Using immunohistochemical (IHC) 
evaluation this research would investigate the potential 
of CM of UC-MSC obtained from Wistar mice with a 
focus on proteins TGF-β1, SOX-9, type II collagen and 
aggrecan expression in a damaged cartilage wound. 
 
MATERIALS AND METHODS 
This research was performed using 24 Wistar mice 
3 months old that underwent surgery within its medial 
condyle of the femur in right hind feet on weight bear-
ing area. The samples were divided into 6 groups. Three 
control groups were 2(K2), 3(K3) and 4(K4) months, 
and three treatment groups were 2(E2), 3(E3) and 4(E4). 
The duration of the study was 4 months. This study has 
been approved by Ethical Clearance Commission of 
Gajah Mada University, Yogyakarta, in Mei 6th 2015 
(Letter number: 263/KEC-LPPT/V/2015). 
 
Isolation and cultivation of UCMSCs  
The umbilical cord was obtained from 19 days preg-
nant Wistar mice by caesarian section according to 
standard procedures. Briefly, under sterile conditions, 
one centimeter of umbilical cord was washed with 10% 
betadine and sterile NaCl. Next, that slash was placed 
inside a centrifuge tube containing transport media Dul-
becco’s Eagle Modified Medium (DMEM) with 200 
µg/L penicillin, 200 µg/mL streptomycin, and 200 µg 
/mL fungi zone). Next, the cord was cut in 20 mm3 sizes 
and cultured using an enzymatic technique. This cord 
slash was further diluted with trypsin/EDTA 0.25% and 
incubated for 30 minutes at 37°C. About 2 cc of com-
plete medium (DMEM 1×, 10% fetal bovine serum, 50 
µg/mL penicillin streptomycin, and 2.5 µg/mL fungi 
zone) was added to the tube already containing the cord 
that had been metabolized by the enzyme. It was then 
centrifuged at 3,000 rpm for 10 minutes at 4°C. The su-
pernatant was removed and the cell suspension was 
mixed with complete medium and incubated at 37°C 
and 5% CO2. It was replaced every three days until cell 
growth reached a confluence of 80%. Afterward, micro-
scopic examination was performed using Hematoxylin 
and Eosin (H&E), Giemsa and Sirius Red staining to 
confirm the existence of the cells, and further confirm 
they are umbilical cord mesenchymal stem cells (UC-
MSC). 
 
Production of conditioned medium 
Cultures of UC-MSC that have reached 80% con-
fluence were harvested using trypsin. Following, trypsin 
neutralization, the cell suspension was centrifuged at 
3,000 rpm for 10 minutes. The supernatant was dis-
carded and the cell pellet was washed three times with 
PBS. The cell pellet was resuspended in fresh medium 
at 10,000 cells per mL. Next, the stem cells were pushed 
towards an embryoid body and seeded onto a culture 
plate with full medium until confluence among these 
bodies were formed. The production of pre-condition 
medium was created by washing the embryoid body cul-
ture with sterile PBS and filling the culture plate with 10 
mL of complete medium without serum. After 48 hours, 
the pre-condition medium was stored at -20°C prior to 
use. 
 
Mice treatment with conditioned medium 
Prior to the treatment, the Wistar received anesthe-
sia of ketamine : xylazine (9 : 1). Next, the Wistar were 
intentionally damaged using manual mechanical drilling 
in the medial condyle femur cartilage (750 rpm) with 
Kirshner wire diameter 1 mm and depth 1 mm to make 
a sharp slope base cartilage lesion. Afterward, they were 
divided into 6 groups, 3 control groups (K2, K3, K4) 
and 3 treatment groups (P2, P3, P4). The treatment  
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Figure 1. IHC results from the articular cartilage network joint 
(left panel), photomicrograph at 400×. (a) The chon-
drocytes with TGFB1 expression are characterized by 
the brown color of the cell cytoplasm (arrows). A. Con-
trol 2nd month, B. Control 3rd months, C. Control 4th 
months, D. Treatment 2nd months, E. Treatment 3rd 
months and F. Treatment 4th months. (b) Graphic of 
the calculation analysis of all preparations of joint car-
tilage tissue (right panel). The X-axis is the treatment 
time group and Y axis represents the mean expression 
of TGFB1. 
 
groups were administered an injection of 1 cc/kg of body 
weight pre-condition medium 5 times over 1-week inter-
val. The Wistar were observed at 2nd (P2 groups), 3rd (P3 
groups), and 4th (P4 groups) months of evaluation. At 
this time, animals were humanely euthanized and the 
cartilage was extracted. Articular cartilage tissue was 
placed inside a tube containing 10% formalin. Biopsy 
samples were sent to the Biochemistry-Biomolecular La- 
boratory of Medical Faculty - Brawijaya University, Ma 
lang. 
Tissue processing (fixation and paraffin embedding) 
and slide preparation of 4 µm cut thickness using a ro-
tary microtome was performed. An immunohistochem-
istry technique was performed to observe the protein ex-
pression of TGF-β1, SOX-9, Collagen type 2 and Aggre-
can using specific antibodies purchased from Santa Cruz 
Biotech (USA) and immunohistochemistry kit using D-
Bio Sys Immunostaining kit (Netherland). The sample 
were reacted with primary antibody of mouse anti Col-
2 (COL2A1 Antibody (M2139) cat#: sc-52658), TGFβ1 
(TGF-β1 Antibody (3C11) cat#: sc-130348), Sox-9 (Sox-
9 antibody (E-9), cat#: sc-166505) and aggrecan (aggre-
can antibody (4F4), cat#: sc-33695) for 24 hours at 4°C, 
then cleaned with PBS pH 7.4 three times for 5 minutes. 
The samples were incubated using secondary antibody 
of biotin (rabbit anti-mouse IgG biotin labelled) for 1 h 
at room temperature, then washed with PBS pH 7.4 
three times for 5 minutes. Strep Avidin-Horse Radin Pe-
roxidase (SA-HRP) were added to the slides and incu-
bated for 40 minutes then washed with PBS pH 7.4 three 
times for 5 minutes. Diamano Benzidine (DAB) were 
added to the slides and incubated for 10 minutes then 
washed with PBS pH 7.4 three times for 5 minutes. 
Counter staining the slides with Mayer Hematoxylen for 
10 minutes then washed with aquadest and dried. Fi-
nally, the slides were mounted with entellan and covered 
with cover glass. The results were evaluated using a mi-
crograft photo using a Nikon E-100 microscope and 
Sony ICLEA7 camera with 400× magnification. Lastly, 
the expression was analyzed using immunoratio soft-
ware (freeware from Institute of Biomedical Technology, 
University of Tampere). 
 
Statistical analysis 
Control and experimental groups were analyzed us-
ing statistic parametric ANOVA and descriptively in 
mean ± SD or median, frequency is presented in per-
centage. For normality or distribution, we use Kolmogo-
rov-Smirnov test and two independent T-test for normal 
distribution data, p < 0.05 indicated a statistically signif-
icant difference. 
 
RESULTS AND DISCUSSION 
To investigate the potential role of conditioned me-
dium of UC-MSC in articular cartilage repair this study  
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(b) 
Figure 2.  IHC results from the articular cartilage network joint 
(left panel), photomicrograph at 400×. (a) The chon-
drocytes with the SOX-9 expression are characterized 
by the brown color of the cell nucleus (arrow). A. Con-
trol 2nd month, B. Control 3rd months, C. Control 4th 
months, D. Treatment 2nd months, E. Treatment 3rd 
months and F. Treatment 4th months. (b) Graphic of 
the calculation analysis of all preparations of joint car-
tilage tissue (right panel). X axis is the treatment time 
group and axis Y represents the mean of SOX-9 expres-
sion. 
used immunohistochemical techniques, with a peroxi-
dase system, to show the expression of TGF-β1, SOX-9,  
type II collagen and aggrecan proteins. 
The expression of TGF-β1 was evident in all study 
samples. Figure 1 shows that TGF-β1 is expressed in the 
cytoplasm of the chondrocytes of the tegmental area, as 
well as the transitional layer of the joint cartilage tissue. 
Using statistical analysis demonstrated that TGF-β1 ex-
pression in the treatment group increased significantly 
when compared with the control group (bottom). Ex-
pression of TGF-β1 (p > 0.05) between the 2nd, 3rd, and 
4th observational groups in the negative control group 
(untreated mice). Overall, the expression of TGF-β1 in 
the treatment group demonstrated a gradual increase 
(months 2nd, 3rd, and 4th) and was significantly different 
in comparison with the control group (B) (p < 0.05).  
Similar values were observed for the expression of 
SOX-9 (p > 0.05) between the 2nd, 3rd, and 4th observa-
tional groups and the negative control group (untreated 
mice). Furthermore, there was a significant difference in 
the expression of SOX-9 (p < 0.05) between the 2nd, 3rd, 
and 4th observation groups in the treatment group (ad-
ministering fasting MSC CM). SOX-9 expression 
demonstrated the most significant difference in the 3rd 
month expression (12.00 ± 0.82b) and 4th month (15.25 
± 1.5c) of the treatment group (Figure 2). 
Type II collagen expression was also observed in 
each study sample. This result indicated that type II co- 
lagen is widely expressed in the cell cytoplasm in the 
transitional area of the articular tissue of cartilage of the 
joint. Using statistical analysis, the results showed that 
type II collagen expression was increased significantly 
compared to the control group (bottom). Overall, type 
II collagen expression in the treatment group demon-
strated a gradual increase (2nd, 3rd, and 4th month) and 
was observed to be significantly different when com-
pared to the control group (p < 0.05). Additionally, the 
expression of type II collagen under control conditions 
began in the 4th month (p < 0.05). 
The aggrecan expression (p > 0.05) was not signifi-
cantly different between the 2nd, 3rd, and 4th observa-
tional groups in the negative control group (untreated 
mice). Based on the mean value of aggrecan expressions, 
the values were similar. The significant difference in ag-
grecan expression (p < 0.05) was observed in the analysis 
between the 2nd, 3rd, and 4th month observational groups 
of the treatment group (MSC). Based on the mean val-
ues of aggrecan expression, there was a significant in-
crease in the 4th month. While in the 2nd and 3rd months 
aggrecan expression remained the same (Figure 3). 
UC-MSC are considered medical waste and the col-
lection is noninvasive. Therefore, access to UC-MSC has  
0
5
10
15
20
2nd Month 3rd Month 4th Month
SO
X
9 
Ex
pr
es
si
on
 (
%
 c
el
l)
Time
Control Treatment
Immunohistochemistry Evaluation of TGF-β1, SOX-9  
  
 
JTLS | J. Trop. Life. Science 25 Volume 8 | Number 1 | January | 2018 
(a) 
 
(b) 
Figure 3. IHC results from the articular cartilage network joint 
(left panel), photomicrograph at 400×. (a) Chondro-
cytes with an expression of aggrecans are characterized 
by the brown color of the cell cytoplasm (arrows). A. 
Control 2nd month, B. Control 3rd months, C. Control 
4th months, D. Treatment 2nd months, E. Treatment 3rd 
months and F. Treatment 4th months. (b) Graphic of 
the calculation analysis of all preparations of joint car-
tilage tissue (right panel). The X axis is the treatment 
time group and the Y axis represents the average of the 
aggrecan expression. 
 
not been burdened with ethical problems [10]. MSC 
conditioned medium (CM) could be defined as secreted 
factors alone that are referred to as the secretome or ex- 
osome without the stem cells. In addition, CM is poten-
tially less allergenic according to the selected proteins 
that are transplanted to some tissues. In our study, we 
analyzed a group of proteins that are potentially found 
in the medium and have a potential to be beneficial in 
cartilage repair. The growth, development, maintenance, 
and improvement of articular cartilages are strictly reg-
ulated by multiple signaling pathways performed by sev-
eral bioactive factors [11]. 
TGF-β1 is an especially significant factor in the 
chondrogenic differentiation of MSCs. It is considered 
to be a potent stimulator for proteoglycan and type II 
collagen synthesis [12]. Ye Li et al. reported that the ex-
pression of TGF-β1 was increased in the condylar carti-
lage of an injurious model of OA [7]. Injecting TGF-β1 
into the periosteum of the femur stimulates chondrocyte 
differentiation and cartilage formation [13]. Addition-
ally, we observed that the expression of TGF-β1 was 
slightly increased in all experimental groups, across all 
time points, when compared to the control groups. 
There are two important proteins, SOX-9 and RUNX2,  
which function as transcription regulators of the TGF-
β1 gene [14]. We speculate that the administration of 
UC MSC-CM activated one or both of the above regu-
latory proteins (SOX-9 and RUNX2), resulting in in-
creased expression of TGF-β1. Further, this is in line 
with the research of Venturin et al. who reported that 
TGF-β1 is expressed in all the differentiating chondro-
progenitor and chondrocytes in the proliferative zone 
[15]. 
SOX-9 is expressed in all chondroprogenitor cells, 
predominantly in mesenchymal condensations and car-
tilage. Cao et al. also found that the repair of cartilage 
defects can be enhanced by SOX-9 transduction [16]. 
They reported that the articular cartilage defects treated 
with MSC overexpressing SOX-9 showed the signifi-
cantly better integration of the repair tissue at the inter-
face with the surrounding normal articular cartilage 
when compared to the other groups. It is well docu-
mented that TGF-β induces expression of a transcrip-
tional factor SOX-9 in its signaling pathway [8]. In our 
study, we found that SOX-9 expression was greatly in-
creased. We suggest that a high level of SOX-9 expres-
sion will have beneficial effects on cartilage repair. 
Type II collagen comprises more than 90% of the 
collagen found in adult articular (hyaline) cartilage. In 
this study, we observed that type II collagen was in-
creased in all samples. This suggests that the CM con-
tains potent components for activation of those proteins 
and displays promising potential for cartilage repair. It 
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is known that SOX-9 is a potent activator in the for-
mation of collagen type II [15], which is a component 
of cartilage. Moreover, this is the predominant type of 
collagen in cartilage. The extracellular matrix is also 
comprised of other specific collagens such as type IX and 
XI [17]. Following the increase in SOX-9 mRNA expres-
sion, the production of type II collagen, aggrecan, and 
cartilage oligomeric matrix protein (COMP) is observed 
[8]. 
Aggrecan is one of the major structural macromol-
ecules of cartilage. Aggrecan function is to resist any 
compressive forces by maintaining the osmotic pressure 
balance in cartilage [18]. According to our study, we 
found that aggrecan expression was significantly in-
creased in all samples. We speculate that aggrecan pro-
duction plays a critical role in cartilage repair techniques 
by maintaining the collagen network. Therefore, aggre-
can participates in both the demise and survival of artic-
ular cartilage. 
This suggests that there has been an increase in tis-
sue growth according to the initial hypothesis referring 
to studies conducted by Mehrabani et al. [19] who ex-
amined cartilage defects in 12 rabbits, in which treat-
ment groups were given mesenchymal stem transplan-
tation. The results of the study suggest that the nature 
of the predominant tissue in the transplant group had a 
higher score than the control group.  
This study has limitations to find a solution in treat-
ing cartilage defects, damaged by trauma. The outside 
problem is not discussed. An update of this study was 
the beginning of the further study for clinical experi-
mental to find a solution to treat the problem of cartilage 
lesion in human as an effective, inexpensive, and con-
venient alternative choice. 
  
CONCLUSION 
Conditioned medium from CM-UC-MSC contains 
proteins and tissue regenerative agents, which are se-
creted by the stem cells and allow for cellular interac-
tions between cell-to-cell and their microenvironment 
for successful chondrogenesis. Results from our study 
indicate that when evaluated using immunohistochem-
istry, CM from UC-MSC increases the expression of 
protein TGF-β1, SOX-9, type II collagen and aggrecan. 
These increased proteins are closely related to chondro-
genesis in cartilage defects in a Wistar rat. 
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